Skip to main content

Table 1 Baseline characteristics of the study participants

From: Effect of probiotic supplementation on lipoprotein-associated phospholipase A2 in type 2 diabetic patients: a randomized double blind clinical controlled trial

 

Probiotic (n = 34)

Mean±SD

Placebo (n = 34)

Mean±SD

P Value

Age (year)

55.6 ± 4.7

56.5 ± 4.8

0.4

Sex, n (%)

  

0.3

male

11 (32%)

8 (24%)

female

23 (68%)

26 (76%)

T2D duration (year)

8.03±4.3

7.94±5.3

0.7

Anthropometrics

   

Weight (kg)

81±11.06

77.9±11.4

0.35

BMI (kg/m2)

31.2±3.3

31.1±3.4

0.6

WC (cm)

105.7±8.2

105.8±9.6

0.95

FM (kg)

28.2±7

28.9±6.6

0.86

FFM (kg)

52±9.8

49.07±8.1

0.08

Physical activity level

   

High, n (%)

2 (5.8%)

1 (3%)

0.16

Moderate, n (%)

12(35.2%)

6 (17.6%)

Low, n (%)

20 (58.8%)

27 (79.3%)

  1. BMI body mass index, FM; fat mass, FFM; fat free mass, FBS fasting blood sugar, HbA1c glycated hemoglobin, HOMA-IR homeostasis model assessment-estimated insulin resistance, TC total cholesterol, TG: Triglyceride, HDL: High Density of Lipoprotein, LDL: Low Density of Lipoprotein, Lp-PLA2 lipoprotein phospholipase A2, * Significant difference (p < 0.05). Data are presented as Mean ±SD and Frequency (Percent). Student t-test and chi-square test were used to compare quantitative and qualitative variables, respectively